Virbac Stock Rebounds and Approaches its 200-Day Moving Average
The veterinary laboratory in Carros is recovering mid-session in a Parisian market strongly trending upwards following ECB announcements. The stock is attempting to reconnect with its medium-term technical benchmarks after several sessions of consolidation.
A Moderate Rebound Bringing the Price Close to the 200-Day Moving Average
Virbac stock has risen by 1.46% to €347.50, up from €342.50 the previous day. The movement remains modest compared to the SBF 120 session, which is up by 2.2%, placing the stock at the 68th position in the index. Today's increase brings the price close to the 200-day moving average (MM200) at €348.96, a mere -0.42% difference.
However, the stock remains below its 20-day moving average (MM20) of €352.88 (-1.52% difference) and its 50-day moving average (MM50) of €359.05 (-3.22% difference), indicating that the medium-term momentum remains fragile. The RSI at 40 indicates a lack of tension, following a 1.28% decline over the past month.
A Rebound in a Parisian Market Boosted by ECB's Decision
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The session's context is favorable for European stocks. The ECB has raised its three key interest rates by 25 basis points, the first increase since September 2023, setting the deposit facility rate at 2.25% starting June 17. The institution justifies its decision with a Eurozone inflation rate of 3.2% in May, driven by energy prices. The CAC 40 is up by 2.27% and the SBF 120 by 2.2%, while the VIX has dropped by 16% to 18.66.
Virbac, whose business is minimally affected by interest rates and oil prices, captures part of this movement without being among the leaders. The stock maintains a year-to-date gain of 8.76%. The support at €339 and resistance at €372 now frame the trading range, with crossing the MM200 being a condition for moving towards the higher end of the band.
SectorPharmacie et biotechnologies›Pharmacie, vaccins et santé animale
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 9M 2026
Key reported figures
Revenue: 1 168 millions d'euros
Quarterly revenue: 1 168 millions d'euros
Guidance from the release
Notre solide performance à fin septembre 2026 nous permet de viser le haut de notre fourchette initiale de croissance du chiffre d'affaires
Risks mentioned
Effets de change défavorables impactant la croissance réelle (croissance réelle +5,9% vs +7,9% à taux constants)
Pression concurrentielle persistante sur les vaccins porcins en Asie de l'Est et pressions tarifaires au segment Animaux d'élevage
Exposition au Moyen-Orient et suivi des tendances inflationnistes (énergie) malgré anticipation d'impacts limités
Opportunities identified
Croissance soutenue des plateformes Supercharge (+11% environ) couvrant petfood, reproduction, dentaire, mobilité, otologie, endocrinologie et ruminants
Intégration fluide de Thyronorm dans la franchise d'endocrinologie avec contribution de +1 point de croissance et +0,5 point d'Ebit ajusté
Redémarrage réussi de la production du contrat majeur de façonnage en Amérique du Nord (juillet 2026) après contrainte réglementaire temporaire
Outlook / guidance
Expected revenue: 1 575 millions d'euros
Management commentary: « Bien que nos perspectives pour l'ensemble de l'année 2026 restent inchangées, notre solide performance à fin septembre (croissance de +7,9%) nous permet de viser la borne haute de notre fourchette de croissance du chiffre d'affaires de 5,5 % à 7,5 % à PCC »
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
